Comorbidities in primary aldosteronism

Hormone and Metabolic Research

Volumn 42, Issue 6, 2010, Pages 429-434

  Quinkler, M ^a   Born Frontsberg, E ^a   Fourkiotis, V G ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Aldosterone; Hypertension; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE ANTAGONIST;

ADRENALECTOMY; ALDOSTERONE TISSUE LEVEL; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL; BRAIN; BRAIN DISEASE; COMORBIDITY; DISEASE COURSE; ESSENTIAL HYPERTENSION; HEART; HUMAN; KIDNEY; KIDNEY INJURY; MENTAL DISEASE; METABOLIC SYNDROME X; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; REVIEW; SLEEP APNEA SYNDROME; TISSUE LEVEL;

BLOOD VESSELS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; COMORBIDITY; HEART; HUMANS; HYPERALDOSTERONISM; KIDNEY DISEASES; MENTAL DISORDERS; METABOLIC SYNDROME X; SLEEP APNEA SYNDROMES;

EID: 77952923660     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0029-1243257     Document Type: Review

References (80)

1. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006 48 2293-2300
2. Rayner BL, Opie LH, Davidson JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000 90 394-400
3. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000 85 1863-1867
4. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000 85 2854-2859
5. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994 21 315-318
6. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000 14 311-315
7. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001 37 699-705
8. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004 89 1045-1050
9. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005 51 386-394
10. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K, Zamboulis C. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008 371 1921-1926
11. Kaplan NM. Is there an unrecognized epidemic of primary aldosteronism? Con Hypertension 2007 50 454-458
12. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension 2003 42 161-165
13. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002 40 892-896
14. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004 22 2217-2226
15. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003 17 349-352
16. Umpierrez GE, Cantey P, Smiley D, Palacio A, Temponi D, Luster K, Chapman A. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 2007 30 1699-1703
17. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) 2007 113 267-278
18. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci U S A 2002 970 89-100
19. Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev 2008 29 133-154
20. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993 21 929-933
21. Rizzoni D, Paiardi S, Rodella L, Porteri E, De CC, Rezzani R, Boari GE, Zani F, Miclini M, Tiberio GA, Giulini SM, Rosei CA, Bianchi R, Rosei EA. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J Clin Endocrinol Metab 2006 91 2638-2642
22. Rizzoni D, Muiesan ML, Porteri E, Salvetti M, Castellano M, Bettoni G, Tiberio G, Giulini SM, Monteduro C, Garavelli G, Gabiti-Rosei E. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 1998 32 985-992
23. Holaj R, Zelinka T, Wichterle D, Petrak O, Strauch B, Widimsky J Jr. Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007 25 1451-1457
24. Bernini G, Galetta F, Franzoni F, Bardini M, Taurino C, Bernardini M, Ghiadoni L, Bernini M, Santoro G, Salvetti A. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens 2008 26 2399-2405
25. Strauch B, Petrak O, Wichterle D, Zelinka T, Holaj R, Widimsky J Jr. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens 2006 19 909-914
26. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008 168 80-85
27. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008 19 88-90
28. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001 12 308-314
29. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 341 709-717
30. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 348 1309-1321
31. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003 108 1831-1838
32. Suzuki T, Abe H, Nagata S, Saitoh F, Iwata S, Ashizawa A, Kuramochi M, Omae T. Left ventricular structural characteristics in unilateral renovascular hypertension and primary aldosteronism. Am J Cardiol 1988 62 1224-1227
33. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996 27 1039-1045
34. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997 95 1471-1478
35. Tsioufis C, Tsiachris D, Dimitriadis K, Stougiannos P, Missovoulos P, Kakkavas A, Stefanadis C, Kallikazaros I. Myocardial and aortic stiffening in the early course of primary aldosteronism. Clin Cardiol 2008 31 431-436
36. Shigematsu Y, Hamada M, Okayama H, Hara Y, Hayashi Y, Kodama K, Kohara K, Hiwada K. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension 1997 29 723-727
37. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007 50 911-918
38. Muiesan ML, Salvetti M, Paini A, Gabiti-Rosei C, Monteduro C, Galbassini G, Belotti E, Aggiusti C, Rizzoni D, Castellano M, Gabiti-Rosei E. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008 52 529-534
39. Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, Boscaro M. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 2007 25 177-186
40. Porodko M, Auer J, Eber B. Conn's syndrome and atrial fibrillation. Lancet 2001 357 1293-1294
41. Conn JW, Knopf RF. Clinical characteristics of primary aldosteronism from analysis of 145 cases. Am J Surg 1964 107 159-172
42. Abdo A, Bebb RA, Wilkins GE. Ventricular fibrillation: an extreme presentation of primary hyperaldosteronism. Can J Cardiol 1999 15 347-348
43. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, Kimura G. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999 33 261-266
44. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005 45 1243-1248
45. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Endres S, Quinkler M. Cardio- and cerebrovascular comorbidites of hypo- and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 2009 94 1124-1130
46. Fallo F, Veglio F, Bertello C, Sonino N, Della MP, Ermani M, Rabbia F, Federspil G, Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006 91 454-459
47. Duprez DA, Bauwens FR, De Buyzere ML, De Backer TL, Kaufman JM, Van HJ, Vermeulen A, Clement DL. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993 71 17A-20A
48. Lawes CM, Vander HS, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008 371 1513-1518
49. Miro O, Pastor P, Pedrol E, Mallofre C, Grau JM, Cardellach F. Cerebral vascular complications in Conn's disease: report of two cases. Neurologia 1995 10 209-211
50. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest 1995 18 370-373
51. Mulatero P, Caserta M, Bertello C, Schiavone D, Verhovez A, Giraudo G, Morello F, Veglio F. Aldosterone as an independent factor in cerebrovascular damage. Clin Exp Hypertens 2008 30 785-797
52. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998 31 451-458
53. Stowasser M, Gordon RD. Familial hyperaldosteronism. J Steroid Biochem Mol Biol 2001 78 215-229
54. Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995 13 1801-1802
55. Danforth DN Jr, Orlando MM, Bartter FC, Javadpour N. Renal changes in primary aldosteronism. J Urol 1977 117 140-144
56. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, Kanashiki M, Saito Y, Ota H, Nose T. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006 69 1264-1271
57. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006 332 1426
58. Rossi GP, Mantero F, Pessina AC. Response to Renal Function in Primary Aldosteronism: Is Glomerular Hyperfiltration a Hallmark of Primary Aldosteronism Further Results from the Primary Aldosteronism? Prevalence in Hypertension (PAPY) Study. Hypertension 2006 48 e111-e112
59. Ribstein J, Du CG, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 2005 16 1320-1325
60. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006 295 2638-2645
61. Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Meisinger C, Holle R, Endres S. Risk Factors Associated with a Low Glomerular Filtration Rate in Primary Aldosteronism. J Clin Endocrinol Metab 2009 94 869-875
62. Fox CS, Larson MG, Hwang SJ, Leip EP, Rifai N, Levy D, Benjamin EJ, Murabito JM, Meigs JB, Vasan RS. Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int 2006 69 2064-2069
63. Novello M, Catena C, Nadalini E, Colussi GL, Baroselli S, Chiuch A, Lapenna R, Bazzocchi M, Sechi LA. Renal cysts and hypokalemia in primary aldosteronism: results of long-term follow-up after treatment. J Hypertens 2007 25 1443-1450
64. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004 125 112-117
65. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007 131 453-459
66. Sonino N, Fallo F, Fava GA. Psychological aspects of primary aldosteronism. Psychother Psychosom 2006 75 327-330
67. Khurshid KA, Weaver ME. Conn's syndrome presenting as depression. Am J Psychiatry 2005 162 1226
68. Malinow KC, Lion JR. Hyperaldosteronism (Conn's disease) presenting as depression. J Clin Psychiatry 1979 40 358-359
69. Murck H, Held K, Ziegenbein M, Kunzel H, Koch K, Steiger A. The renin-angiotensin-aldosterone system in patients with depression compared to controls a sleep endocrine study. BMC Psychiatry 2003 3 15
70. Emanuele E, Geroldi D, Minoretti P, Coen E, Politi P. Increased plasma aldosterone in patients with clinical depression. Arch Med Res 2005 36 544-548
71. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007 30 2349-2354
72. Marigliano A, Tedde R, Sechi LA, Pala A, Pisanu G, Pacifico A. Insulinemia and blood pressure. Relationships in patients with primary and secondary hypertension, and with or without glucose metabolism impairment. Am J Hypertens 1990 3 521-526
73. Sechi LA, Melis A, Tedde R. Insulin hypersecretion: a distinctive feature between essential and secondary hypertension. Metabolism 1992 41 1261-1266
74. Shimamoto K, Shiiki M, Ise T, Miyazaki Y, Higashiura K, Fukuoka M, Hirata A, Masuda A, Nakagawa M, Iimura O. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J Hum Hypertens 1994 8 755-759
75. Ishimori M, Takeda N, Okumura S, Murai T, Inouye H, Yasuda K. Increased insulin sensitivity in patients with aldosterone producing adenoma. Clin Endocrinol (Oxf) 1994 41 433-438
76. Haluzik M, Sindelka G, Widimsky J Jr, Prazny M, Zelinka T, Skrha J. Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. J Hum Hypertens 2002 16 41-45
77. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006 91 3457-3463
78. Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA, Fardella CE. A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens 2007 25 2125-2130
79. Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X, Plouin PF. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009 53 605-610
80. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000 49 1751-1760